Business Wire

Quanergy Secures First AI-Powered 3D LiDAR Integration with Industry Leading Security Center Platform From Genetec

30.6.2020 16:00:00 EEST | Business Wire | Press release

Share

Quanergy Systems, Inc., a leading provider of LiDAR (Light Detection and Ranging) sensors and smart perception solutions, today announced the first commercial integration of 3D AI-powered LiDAR solutions with the Genetec Inc. (“Genetec”) Security Center unified security platform. The integrated solutions will provide advanced people flow and occupancy management in smart spaces as well as enhanced threat detection and surveillance in high-security environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005262/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quanergy Secures First AI-Powered 3D LiDAR Integration with Industry Leading Security Center Platform From Genetec (Graphic: Business Wire)

Quanergy’s high-performance AI-powered 3D LiDAR solution will be integrated to the Genetec unified security platform, allowing its use in multiple specialized Security Center modules including Restricted Security Area, Passenger Flow Analytics, and Occupancy Management package to help automate security, people counting and social distancing applications. Adding Quanergy’s 3D LiDAR and sensor data flow to Genetec Security Center provides increased real-time accuracy for a clearer read on actual footfall traffic, occupancy and proximity in a wide variety of industrial applications from transit systems, airports and industrial facilities to public facing businesses including banking and retail.

“Quanergy’s LiDAR flow management solutions bring a new level of real-time 3D insights that make them ideal for any environment where high accuracy and operational intelligence are critical,” said Enzo Signore, CMO at Quanergy. “Our tight integration with the Genetec Security Center unified platform enables a unique level of automation of many applications across retail, critical infrastructure, airport, seaport, enterprise, and smart cities.”

“We are excited to be integrating Quanergy's 3D LiDAR flow management solutions within Genetec Security Center,” said David Lenot, Airport Product Leader at Genetec. “By bringing their 3D LiDAR sensor data into the traffic and passenger flow modules in our unified platform, we’re helping airports and other organizations address pressing needs while also unlocking new insights into their security operations.”

Quanergy’s AI-powered LiDAR solution accurately and reliably monitor wide areas in real-time in a variety of environments without compromising people’s privacy. The new integrated 3D LiDAR-based solutions will provide:

  • 98%+ detection accuracy: Quanergy QORTEX People Counter accurately detects the number and direction of people, entering in and out of common areas. This can also be used to detect tailgating and increase the security of critical areas. QORTEX People Counter accuracy is significantly higher than camera-based system.
  • Dramatic reduction in false alarms: Quanergy’s QORTEX DTC solution significantly reduces false alarms typical of camera-based systems due to its advanced object detection, tracking, and classification capabilities.
  • 5X - 20X lower TCO (total cost of ownership) than camera-based systems due to very wide coverage (360 degree) and long range (40-70m). A single sensor can cover the area upwards of 8000 m2. This broad area coverage also reduces installation and cabling costs.
  • Rich 3D, real-time data: Quanergy’s flow management solutions provide accurate centimeter level information about the number of objects, their spatial location, direction, and speed. Quanergy solutions also can detect distance between people to accurately monitor and manage social distancing policies.
  • Privacy protection without compromising or storing private personal information. The LiDAR solutions do not use facial recognition technology nor require opt-in by users; they therefore guarantee the anonymity of people and pose zero PII risk.
  • Reliable & Scalable: Works in all lighting and atmospheric conditions so security systems can effectively operate 24/7.

The integrated solutions are available and can be ordered immediately.

For more information, please visit us at www.quanergy.com/contact.

About Quanergy

Quanergy was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers a high-performance AI-powered LiDAR platform designed to accelerate the automation of key business processes to increase productivity, efficiency, and safety of our 3D world. By providing actionable insights to organizations across major industries including, mapping, security, smart cities and smart spaces, industrial automation and transportation, Quanergy is enabling its partners and their end-users to deploy innovative solutions to drive their business growth and ultimately, improve the quality of life for people around the world. For more information, visit www.quanergy.com.

© Genetec Inc., 2020. Genetec, Security Center and the Genetec logo are trademarks of Genetec Inc. and may be registered or pending registration in several jurisdictions. Other trademarks used in this document may be trademarks of the manufacturers or vendors of the respective product.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Neal Stein, Red Javelin Communications
321-473-7407
neal@redjavelin.com

Sona Kim, Quanergy
408.245.9500
media@quanergy.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye